Abstract: Techniques for improved machine learning are provided. A notification to be provided to a user engaged in a therapeutic treatment is identified, and a set of user characteristics associated with the user is determined. A target time to provide the notification to the user is identified by processing the set of user characteristics using a machine learning model, and the notification is transmitted to the user at the target time.

Abstract: Disclosed herein is a process for producing a lactoferrin powder. The process comprises extracting lactoferrin from a native lactoferrin-containing substance and concentrating the extracted lactoferrin to produce a liquid concentrate in which the extracted lactoferrin has an improved stability. The liquid concentrate is then pasteurised by heating to a temperature and for a time effective to do so, after which the pasteurized liquid concentrate is dried under non-denaturing conditions to produce a lactoferrin powder in which substantially all of the lactoferrin is native lactoferrin.

Abstract: Disclosed are anti-IL-25 binding molecules and methods of using said binding molecules in the treatment of rhinoviral infection, coronavirus infection, airway inflammation, rheumatoid arthritis, asthma, osteoarthritis, bone erosion, intraperitoneal abscesses and adhesions, inflammatory bowel disorder, allograft rejection, psoriasis, certain types of cancer, angiogenesis, atherosclerosis, cystic fibrosis and multiple sclerosis. Also disclosed are methods of using said binding molecules in the treatment of inflammation due to microbial infection, autoinflammatory disease, and/or autoimmune disease including, but not limited to rhinoviral infection, coronavirus infection, airway inflammation, rheumatoid arthritis, asthma, osteoarthritis, bone erosion, intraperitoneal abscesses and adhesions, inflammatory bowel disorder, allograft rejection, psoriasis, certain types of cancer, angiogenesis, atherosclerosis, cystic fibrosis and multiple sclerosis.

Abstract: A mammalian expression system comprising an attenuated, recombinant Ranavirus that has at least one foreign expression element using a unique combination of mammalian transcriptional and translational enhancement elements is disclosed. In other contemplated embodiments, a mammalian expression system comprising a virus, wherein the virus is engineered to express at least two vaccine antigens is disclosed. In addition, methods of delivering human antigens to a mammal are disclosed that include: providing a non-mammalian virus, engineering a recombinant virus that can express at least one foreign molecule by modifying the non-mammalian virus, and using the recombinant Ranavirus to express and deliver foreign antigens to a mammal.

Abstract: The present invention relates to compounds and their compositions, and the use of such compounds and compositions in the prevention and/or treatment of respiratory infections, or diseases or conditions associated with coronavirus infections. The compositions comprise therapeutically effective amounts of a TLR2 agonist. Certain embodiments specify that the TLR2 agonist is a pegylated, palmitoylated-cysteine compound of Formula (I), (VI), (VII) or (VIII).

Abstract: Disclosed are compositions and methods related to IL-25 binding molecules.

Abstract: A mammalian expression system comprising an attenuated, recombinant ranavirus strain that has at least one expression element is disclosed. A method of delivering antigens to a mammal is disclosed that includes: providing a mammalian expression system comprising an attenuated, recombinant ranavirus strain that has at least one expression element; and administering to the mammal a therapeutic amount of the attenuated, recombinant ranavirus strain that has at least one expression element.

Abstract: Disclosed are compositions and methods related to IL-25 binding molecules.

Abstract: The present invention relates to methods, compositions and kits for the treatment or prevention of respiratory conditions. In particular, the methods, compositions and kits are particularly useful, but not limited to, the prevention and/or treatment of rhinovirus infection and the prevention and/or treatment of asthma exacerbation. The invention provides a method inhibiting a rhinovirus infection in a subject comprising administering a composition consisting of a compound comprising a TLR2 agonist and a pharmaceutically acceptable carrier.

Abstract: A vaccine vector comprising an attenuated, recombinant ranavirus that has at least one foreign expression element is disclosed. In other contemplated embodiments, a vaccine vector comprising a virus, wherein the virus is engineered to express at least two vaccine antigens is disclosed. In addition, methods of delivering human antigens to a mammal are disclosed that include: providing a non-mammalian virus, engineering a recombinant virus that can express at least one foreign molecule by modifying the non-mammalian virus, and using the recombinant ranavirus to deliver human antigens to a mammal.

Abstract: The invention relates to compounds of formula (I): wherein R1, R2, Y, R4 and R5 are as defined herein. The compounds are intermediates in the synthesis of synthetic bile acids.

Abstract: The invention relates to compounds of formula (I): wherein R1, R2, Y, R4 and R5 are as defined herein. The compounds are intermediates in the synthesis of synthetic bile acids.

Abstract: The present invention concerns: a) an isolated peptide comprising an amino acid sequence which is at least 90% identical to the VP4 amino acid sequence of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and/or b) an isolated peptide comprising an amino acid sequence of at least 100 amino acids which is at least 90% identical to an amino acid sequence located in the last 363 C-terminal amino acids of the RNA polymerase of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and c) a Th1 adjuvant when said immunogenic composition comprises one or more of said isolated peptides.